SPOTLIGHT -
The Senate last week unanimously approved the nomination of FDA commissioner Mark McClellan, MD, PhD, to serve as administrator of the Centers for Medicare & Medicaid Services.
First patient dosed with TLX250-CDx in Italy for ccRCC
With the dosing of the first patient in Italy, Telix’s expanded access program for TLX250-CDx in ccRCC now includes 3 active countries, including the Netherlands and the US.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders
Developed by the AUGS Scientific Committee and Research Agenda Writing Group
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
HSD3B1 CC genotype associated with inferior outcomes in prostate cancer
"Indeed, HSD3B1 appears to be the most common monogenic driver of prostate cancer mortality,” says Nima Sharifi, MD.
EMA recommends approval of enzalutamide for nmHSPC
Astellas expects a decision on EU marketing authorization of enzalutamide in nmHSPC by June 2024.